Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
March 28, 2024 16:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces New Employment Inducement Grant
March 05, 2024 07:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
March 05, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases GAITHERSBURG, Md.,...
Cartesian Therapeutics Announces New Employment Inducement Grants
February 05, 2024 16:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
January 08, 2024 07:10 ET
|
Cartesian Therapeutics, Inc.
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month...
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
January 08, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting...
Selecta Biosciences Announces Merger with Cartesian Therapeutics
November 13, 2023 08:05 ET
|
Selecta Biosciences, Inc.
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset,...
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
October 31, 2023 16:03 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...